Jumbo and Hanshow announce a new partnership to digitize over 700 stores
23.11.2022 10:00:00 EET | Business Wire | Press release
Jumbo, the second largest supermarket chain in the Netherlands which also has stores in Belgium, has announced an exclusive partnership with global retail solutions provider Hanshow to digitally transform its network of stores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005660/en/
Hanshow's electronic shelf labels (ESLs) installed at Jumbo (Photo: Business Wire)
Jumbo was founded in 1921 and currently owns more than 700 stores in the Netherlands and Belgium. It is locally renowned for its wide range of selections and personalized attention to both customers and employees.
With the digital transformation of its business model, Jumbo is becoming one of the leading retailers in Europe. This is driven in part by the Jumbo Tech Campus which facilitates the innovation of Jumbo’s digital solutions and channels to connect its online and offline retail business while strengthening relationships with customers.
The collaboration with Hanshow is a crucial move in Jumbo's digitization strategy. To date, Hanshow’s solutions have been rolled out in over 250 stores. Soon Jumbo will have upgraded all 700 of its stores, with over 11 million Hanshow electronic price tags installed.
“The unique Jumbo formula revolves around a large assortment with the best service at low prices. Correct prices on the shelf and the ability to react quickly and efficiently to market developments are essential for this. The technology of Hanshow contributes to this.” Jumbo said.
At the heart of this digital transformation with Hanshow, the adoption of over 11 million electronic shelf labels (ESLs) will save time and energy across all Jumbo stores. Hundreds of thousands of paper price tags can be saved by this partnership each year, which is also in line with Jumbo’s abiding goal of sustainability. ESLs dramatically increase efficiency for retail operations such as inventory management and faster order picking with LED flashing functions. Additionally, ESLs improve the customer shopping experience with centralized price updates, error-free labeling, and enhanced store appearance.
Powering the systems management of this massive amount of ESL is made possible by adopting the Hanshow SaaS solution via Microsoft Azure. Benefits for Jumbo include reducing costs spent on infrastructure and servers, and if needed the Hanshow technical support team is capable of helping resolve technical issues much faster. Hanshow’s PriSmart ESL and IoT device management system also allows Jumbo to get the systems up and running sooner and the ability to manage and update its pricing network in a faster, more secure, and more accessible way.
“Hanshow solutions can drive sustainability, improve efficiency, eliminate waste, and create new opportunities for Jumbo stores,” notes Sally Liang, General Manager of Europe, Hanshow. “This is an exciting era for retail, and we’re proud to be partnering with a company like Jumbo that is committed to improving its customer experience and operational efficiency through digital retail transformation.”
The cooperation with Jumbo is a significant achievement for Hanshow’s international development. In the future, Hanshow looks forward to cooperating with global customers to further explore the paths of digital transformation, to further optimize digital store solutions, and to provide more comprehensive, intelligent, and efficient digital service upgrades.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005660/en/
Contact information
Joy Wang
tianjiao.wang@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 20266.7.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in patients with refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The data were presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress 2026 on July 2 in Munich, Germany. BOT+BAL demonstrated clinically meaningful long-term survival in a heavily pretreated patient population with historically limited benefit from conventional immune checkpoint inhibitors and few durable treatment options after progression on standard therapies. With extended follow-up, median overall survival was 21.2 months and the three-year overall survival rate was 33%, with the Kaplan-Meier curve showing a plateau beyond two years
LTM Launches BlueVerse™ RightLogic to Address Cyber Risk in AI Era6.7.2026 12:12:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has launched BlueVerse™ RightLogic, a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. AI is now capable of autonomously identifying and exploiting vulnerabilities, while exposure across infrastructure, applications and supply chains continue to expand. This has elevated cyber risk from a technology concern to a board-level priority, with enterprises struggling to maintain visibility and respond at the speed of emerging threats. BlueVerse RightLogic addresses this gap by providing a unified, business-aligned view of enterprise exposure and enabling a shift from fragmented, point-in-time assessments to continuous, evidence-led risk management. The framework combines an end-to-end AI and cyber exposure assessment engine with a structured execution model that spans from assessment to remediation. At the cor
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 11:00:00 EEST | Press release
Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countries published in “The Allianz 3am Report 2026.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260703907741/en/ Allianz / IPSOS “What Worries the World” Study, April – June 2026. Financial worries, which include concerns about “rising cost of living” (71%) and “insufficient income” (51%), increased in seven out of eight countries surveyed year over year, moving up in the ranking of top three worries in Brazil, France, Germany, and the U.K., while remaining stable in Italy. The strongest increases are observed in Australia and Indonesia, where financial concerns have remained the leading worry, as well
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 09:40:00 EEST | Press release
Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in Tokyo on July 6, 2026. Fusion energy has the potential to shift the foundation of energy from natural resources to advanced technology by reproducing, on Earth, the sam
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 08:15:00 EEST | Press release
Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discovery and development of a novel class of payloads for antibody-drug conjugates. The company's platform is built around next-generation N-myristoyltransferase inhibitor (NMTi) payloads, a differentiated mechanism of action designed to address the narrow therapeutic windows and tolerability challenges that have limited earlier generations of ADCs, such as TOPO-1 and tubulin inhibitor payload classes. Myricx Bio's two lead ADC assets, directed towards the established targets B7-H3 and HER2, are designed to bring this differentiated approach to patients across a broad ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom